Literature DB >> 30635355

Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity.

Mojgan Ahmadzadeh1, Anna Pasetto1, Li Jia1, Drew C Deniger1, Sanja Stevanović2, Paul F Robbins1, Steven A Rosenberg3.   

Abstract

CD4+ regulatory T (Treg) cells have an essential function in maintaining self-tolerance; however, they may also play a detrimental role in antitumor immune responses. The presence of elevated frequencies of Treg cells in tumors correlates with disease progression and poor survival in patients with cancer. The antigen specificity of Treg cells that have expanded in the tumor microenvironment is poorly understood; answering this question may provide important insights for immunotherapeutic approaches. To address this, we used a novel combinatorial approach to characterizing the T cell receptor (TCR) profiles of intratumoral Treg cells from patients with metastatic melanoma, gastrointestinal, and ovarian cancers and elucidated their antigen specificities. The TCR repertoires of tumor-resident Treg cells were diverse yet displayed significant overlap with circulating Treg cells but not with conventional T cells in tumor or blood. TCRs isolated from Treg cells displayed specific reactivity against autologous tumors and mutated neoantigens, suggesting that intratumoral Treg cells act in a tumor antigen-selective manner leading to their activation and clonal expansion in the tumor microenvironment. Tumor antigen-specific Treg-derived TCRs resided in the tumor and in the circulation, suggesting that both Treg cell compartments may serve as a source for tumor-specific TCRs. These findings provide insights into the TCR specificity of tumor-infiltrating human Treg cells that may have potential implications for cancer immunotherapy.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635355      PMCID: PMC6685542          DOI: 10.1126/sciimmunol.aao4310

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  39 in total

1.  Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.

Authors:  Gang Zhou; Hyam I Levitsky
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.

Authors:  Dat Q Tran; Heather Ramsey; Ethan M Shevach
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

3.  Immunogenicity of somatic mutations in human gastrointestinal cancers.

Authors:  Eric Tran; Mojgan Ahmadzadeh; Yong-Chen Lu; Alena Gros; Simon Turcotte; Paul F Robbins; Jared J Gartner; Zhili Zheng; Yong F Li; Satyajit Ray; John R Wunderlich; Robert P Somerville; Steven A Rosenberg
Journal:  Science       Date:  2015-10-29       Impact factor: 47.728

4.  Deep sequencing of the TCR-β repertoire of human forkhead box protein 3 (FoxP3)+ and FoxP3- T cells suggests that they are completely distinct and non-overlapping.

Authors:  A Golding; S Darko; W H Wylie; D C Douek; E M Shevach
Journal:  Clin Exp Immunol       Date:  2017-01-09       Impact factor: 4.330

Review 5.  Induced CD4+Foxp3+ regulatory T cells in immune tolerance.

Authors:  Angelina M Bilate; Juan J Lafaille
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

6.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

Authors:  Marc A Gavin; Troy R Torgerson; Evan Houston; Paul DeRoos; William Y Ho; Asbjørg Stray-Pedersen; Elizabeth L Ocheltree; Philip D Greenberg; Hans D Ochs; Alexander Y Rudensky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

7.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Authors:  Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; Steven A Rosenberg
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

8.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

Authors:  Cyrille J Cohen; Yong F Li; Mona El-Gamil; Paul F Robbins; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

9.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

Authors:  Andreas Bonertz; Jürgen Weitz; Dong-Ho Kim Pietsch; Nuh N Rahbari; Christoph Schlude; Yingzi Ge; Simone Juenger; Israel Vlodavsky; Khashayarsha Khazaie; Dirk Jaeger; Christoph Reissfelder; Dalibor Antolovic; Maximilian Aigner; Moritz Koch; Philipp Beckhove
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

Review 10.  Regulatory T cells and Foxp3.

Authors:  Alexander Y Rudensky
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

View more
  67 in total

Review 1.  Metabolic profiles of regulatory T cells in the tumour microenvironment.

Authors:  Disha Rao; Fabienne Verburg; Kathrin Renner; Daniel S Peeper; Ruben Lacroix; Christian U Blank
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

2.  Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation.

Authors:  Zilei Liu; Jie P Li; Mingkuan Chen; Mengyao Wu; Yujie Shi; Wei Li; John R Teijaro; Peng Wu
Journal:  Cell       Date:  2020-10-22       Impact factor: 41.582

3.  Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Authors:  James C Lee; Sadaf Mehdizadeh; Jennifer Smith; Arabella Young; Ilgiz A Mufazalov; Cody T Mowery; Adil Daud; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2020-10-02

4.  Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis.

Authors:  Saige L Pompura; Allon Wagner; Alexandra Kitz; Jacob LaPerche; Nir Yosef; Margarita Dominguez-Villar; David A Hafler
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

5.  Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.

Authors:  Kroopa Joshi; Marc Robert de Massy; Mazlina Ismail; James L Reading; Imran Uddin; Annemarie Woolston; Emine Hatipoglu; Theres Oakes; Rachel Rosenthal; Thomas Peacock; Tahel Ronel; Mahdad Noursadeghi; Virginia Turati; Andrew J S Furness; Andrew Georgiou; Yien Ning Sophia Wong; Assma Ben Aissa; Mariana Werner Sunderland; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Crispin T Hiley; Ehsan Ghorani; José Afonso Guerra-Assunção; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Charles Swanton; Sergio A Quezada; Benny Chain
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

6.  A tumor-specific mechanism of Treg enrichment mediated by the integrin αvβ8.

Authors:  Robert I Seed; Kenji Kobayashi; Saburo Ito; Naoki Takasaka; Anthony Cormier; Jillian M Jespersen; Jean Publicover; Suprita Trilok; Alexis J Combes; Nayvin W Chew; Jocelyne Chapman; Matthew F Krummel; Jianlong Lou; James Marks; Yifan Cheng; Jody L Baron; Stephen L Nishimura
Journal:  Sci Immunol       Date:  2021-03-26

7.  Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.

Authors:  Zohreh Amoozgar; Jonas Kloepper; Jun Ren; Rong En Tay; Samuel W Kazer; Evgeny Kiner; Shanmugarajan Krishnan; Jessica M Posada; Mitrajit Ghosh; Emilie Mamessier; Christina Wong; Gino B Ferraro; Ana Batista; Nancy Wang; Mark Badeaux; Sylvie Roberge; Lei Xu; Peigen Huang; Alex K Shalek; Dai Fukumura; Hye-Jung Kim; Rakesh K Jain
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 17.694

8.  The T cell differentiation landscape is shaped by tumour mutations in lung cancer.

Authors:  Ehsan Ghorani; James L Reading; Jake Y Henry; Marc Robert de Massy; Rachel Rosenthal; Virginia Turati; Kroopa Joshi; Andrew J S Furness; Assma Ben Aissa; Sunil Kumar Saini; Sofie Ramskov; Andrew Georgiou; Mariana Werner Sunderland; Yien Ning Sophia Wong; Maria Vila De Mucha; William Day; Felipe Galvez-Cancino; Pablo D Becker; Imran Uddin; Theres Oakes; Mazlina Ismail; Tahel Ronel; Annemarie Woolston; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Kevin Litchfield; Lucia Conde; José Afonso Guerra-Assunção; Kevin Blighe; Dhruva Biswas; Roberto Salgado; Tom Lund; Maise Al Bakir; David A Moore; Crispin T Hiley; Sherene Loi; Yuxin Sun; Yinyin Yuan; Khalid AbdulJabbar; Samra Turajilic; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Benny Chain; Charles Swanton; Sergio A Quezada
Journal:  Nat Cancer       Date:  2020-05-22

9.  Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.

Authors:  Simon Eschweiler; James Clarke; Ciro Ramírez-Suástegui; Bharat Panwar; Ariel Madrigal; Serena J Chee; Ioannis Karydis; Edwin Woo; Aiman Alzetani; Somaia Elsheikh; C J Hanley; G J Thomas; Peter S Friedmann; Tilman Sanchez-Elsner; Ferhat Ay; Christian H Ottensmeier; Pandurangan Vijayanand
Journal:  Nat Immunol       Date:  2021-06-24       Impact factor: 25.606

Review 10.  Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.

Authors:  Ellen N Scott; Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.